Tissue-signaling research
TB-500
Lyophilized tissue-signaling peptide for preclinical pathway research
TB-500 is a thymosin beta-4 fragment research peptide connected to actin regulation, cell migration, tissue-stress, and wound-model literature.
This product has an available COA with reported batch details and test results.
Open available COAConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesSolo per ricerca di laboratorio. Non per uso umano o veterinario. Non destinato a diagnosticare, trattare, curare, mitigare o prevenire malattie.
Conservare sigillato, freddo, asciutto e protetto dagli sbalzi di calore. Conferma lo stoccaggio specifico del prodotto all'arrivo.
Imballato per garantire la stabilità del transito con supporto per gli ordini disponibile per le rotte con clima caldo.
Batch-linked certificate support is available through the documentation desk.
Contesto di ricerca
Profilo di ricerca TB-500
TB-500 is a synthetic research peptide commonly discussed in relation to thymosin beta-4 biology. Experimental work in this area examines actin binding and sequestration, cell migration, angiogenesis, inflammatory signaling, tissue remodeling, and wound-model endpoints. Researchers should distinguish a marketed TB-500 fragment from full-length thymosin beta-4 because sequence, identity, and experimental behavior may not be interchangeable across publications. This material is generally selected for cell-motility and tissue-stress studies or for comparison with other repair-pathway peptides. Most relevant evidence is preclinical, and literature on thymosin beta-4 cannot automatically be treated as evidence for every fragment, formulation, blend, or catalog lot.
Meccanismo proposto
Usually discussed through thymosin beta-4 biology, particularly binding of monomeric actin through the LKKTET region. Proposed downstream effects include altered cytoskeletal dynamics, cell migration, angiogenesis, inflammatory signaling, and extracellular-matrix remodeling.
Effetti riportati negli studi
- Full-length thymosin beta-4 studies reported increased cell migration, angiogenesis, epithelial repair, and wound closure in selected models.
- Animal studies reported effects on cardiac, corneal, dermal, and musculoskeletal injury markers under specific conditions.
- Commercial TB-500 may not be molecularly identical to full-length thymosin beta-4, so effects cannot automatically be transferred between materials.
Endpoint di ricerca comuni
Actin binding, cell migration, angiogenesis, wound closure, collagen and matrix organization, inflammatory markers, tissue histology, and sequence identity.
Evidenze e limiti
Most evidence concerns thymosin beta-4 or preclinical fragments. Product sequence and identity are essential because direct human TB-500 evidence is limited.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Open the available COA on this page. Before ordering, confirm the named material and listed format; when the order arrives, match the document identifiers to the supplied lot.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.